湯臣倍健股票討論區

Analysts downgrade Byhealth's earnings per share estimates, reflecting a sentiment decline post recent results. The company's revenue growth is expected to lag behind industry peers, indicating increased pessimism about its intrinsic value.

The EPS and share price divergence suggests possible over-hyping of the share price. The market's overreaction to the price drop could present an opportunity. Yet, last year's performance might hint at unresolved challenges.

Byhealth's steady capital reinvestment at decent rates of return could be indicative of its potential as a multi-bagger stock. Although the ROCE return consistency may not seem exciting, it can yield decent share price returns over the long term.